Trial reportWorld journal of gastroenterology2009
Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial.
Trial report in World journal of gastroenterology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 7 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Network Meta-Analysis: Treatments for Acute Alcohol-Associated Hepatitis.Liver international : official journal of the International Association for the Study of the Liver · 2026Pooled it
- Meta-Analysis: Mortality Trends and Risk Factors in Severe Alcohol-Associated Hepatitis.Alimentary pharmacology & therapeutics · 2025Pooled it
- ACG Clinical Guideline: Alcoholic Liver Disease.The American journal of gastroenterology · 2018Guideline
- Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review.Alcoholism, clinical and experimental research · 2016Pooled it
- KASL clinical practice guidelines: management of alcoholic liver disease.Clinical and molecular hepatology · 2013Guideline
- Revision and update on clinical practice guideline for liver cirrhosis.The Korean journal of hepatology · 2012Guideline
- Corticosteroids Versus Pentoxifylline for Severe Alcoholic Hepatitis: A Sequential Analysis of Randomized Controlled Trials.Journal of clinical gastroenterologyPooled it
- Pentoxifylline effects on hospitalized patients with COVID19: A randomized, double-blind clinical trial.International immunopharmacology · 2021Trial
- Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis.World journal of gastroenterology · 2015Trial
- Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial.Trials · 2013Trial
- Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial).Digestive diseases and sciences · 2012Trial
- Stratification and selection of therapies to improve survival in severe alcoholic hepatitis.World journal of hepatology · 2025Review
- Review
- Current Pharmacotherapy and Nutrition Therapy of Alcohol-Associated Liver Disease.Clinics in liver disease · 2024Review
- Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis.Contemporary clinical trials communications · 2023Article
- Effects of Dexamethasone and Pentoxifylline on Mania-like and Depression-like Behaviors in Rats.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Recommendation Reversals in Gastroenterology Clinical Practice Guidelines.Journal of the Canadian Association of Gastroenterology · 2022Article
- Review
- Anti-TNF-α Compounds as a Treatment for Depression.Molecules (Basel, Switzerland) · 2021Review
- Chemokines, cytokines and substance use disorders.Drug and alcohol dependence · 2021Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo compare the efficacy of pentoxifylline and prednisolone in the treatment of severe alcoholic hepatitis, and to evaluate the role of different liver function scores in predicting prognosis.
methodsSixty-eight patients with severe alcoholic hepatitis (Maddrey score > or = 32) received pentoxifylline (n = 34, group I) or prednisolone (n = 34, group II) for 28 d in a randomized double-blind controlled study, and subsequently in an open study (with a tapering dose of prednisolone) for a total of 3 mo, and were followed up over a period of 12 mo.
resultsTwelve patients in group II died at the end of 3 mo in contrast to five patients in group I. The probability of dying at the end of 3 mo was higher in group II as compared to group I (35.29% vs 14.71%, P = 0.04; log rank test). Six patients in group II developed hepatorenal syndrome as compared to none in group I. Pentoxifylline was associated with a significantly lower model for end-stage liver disease (MELD) score at the end of 28 d of therapy (15.53 +/- 3.63 vs 17.78 +/- 4.56, P = 0.04). Higher baseline Maddrey score was associated with increased mortality.
conclusionReduced mortality, improved risk-benefit profile and renoprotective effects of pentoxifylline compared with prednisolone suggest that pentoxifylline is superior to prednisolone for treatment of severe alcoholic hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.